Gilead Sciences, under intense investor pressure to do a significant M&A deal, may have found a target it likes. It is said to be evaluating United Therapeutics, although it finds itself in competition with GlaxoSmithKline and perhaps others.
The Evening Standard, citing unnamed sources, said that Gilead Sciences is considered the most likely candidate to win a bid for United Therapeutics. But the newspaper also said that GSK has Citi and Lazard helping it assess the United, a company founded in 1996 on a pulmonary arterial hypertension (PAH) drug that had been discarded by GSK.
{iframe}http://www.fiercepharma.com/m-a/gilead-and-gsk-are-sizing-up-pah-specialist-united-therapeutics-report-says?utm_medium=nl&utm_source=internal&mrkid=920176&mkt_tok=eyJpIjoiT1dZM05qQXpOMlpoTWpjMSIsInQiOiJkVWtOakR5ZXJLVDNtaE9PNURjTVZMenZmNE9XM2NSUmtQVHZUVVFSTlBSSTVHRCtMRWJyeGxNYWFLUk5nelc5RXhQU3BORDI2UVhMTDIyRFVlMThiTDlTXC9qUVY1aGQ1RGg5cmlUaEZuWFVvZWgrbVpXb0NPT0dnN1N0cUN0XC9QIn0%3D{/iframe}